Acadia has tried to see the positives after a pivotal trial failure with Nuplazid in schizophrenia, but the data bode ill for other label-expansion studies.
Knockout interim data from Acadia’s trials of its antipsychotic in schizophrenia and dementia could make for early approval. But the chances of this are not high.
Failure at a futility analysis blows a big hole in Biogen's pipeline. Can the company buy in growth or will its valuation sink enough for it to become a target?
With few pipeline catalysts this year the pressure is growing on Lundbeck's new chief executive, Deborah Dunsire, to deliver a deal. But the company only has $5bn to…
For biotechs nearing regulatory approval the key is to sell before launch. For buyers, playing the waiting game is a better strategy.
ALKS 5461 is headed back to the clinic or scrapheap, raising questions over whether Alkermes should remain in mental health drug development.
As one headache for Acadia eases another begins, with unconvincing results from a mid-stage depression trial of Nuplazid.
Alnylam has secured its first approval, but history suggests that launch will be far from easy.
The Australian group has found a partner for its lead asset at last, so why is the stock down?